Marksans Pharma cash flow

Latest FY26

Cash from operations: ₹458cr+2,116.8% on FY25
Capital spending: ₹131cr+654.8% on FY25
Free cash flow: ₹328cr+9,608.0% on FY25
Cash from financing: −₹70.9cr−₹6.5 cr in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	98.6	8.3	74.3	51.9
	—	24.1	1.2	11.2	9.1
	—	−27.7	−3.0	−33.8	−12.0
	—	2.9	0.4	−4.3	10.8
	—	−22.4	−0.5	3.0	−0.2
	—	25.2	0.6	5.2	14.7
	—	−1.2	−0.1	−0.1	0.0
	—	−38.7	−19.5	−113	−44.9
	—	−31.4	−7.8	−37.2	−27.5
	—	−0.1	−0.0	−0.3	4.9
	—	−0.2	−0.1	0.8	−0.7
	—	−0.8	−1.6	−22.3	−23.9
	—	0.1	−0.0	−7.3	−2.7
	—	9.4	3.2	31.4	22.4
	—	1.1	0.4	3.3	−46.9
	—	−1.9	1.3	16.1	6.2
	—	0.1	−0.1	0.9	0.5
	—	−0.0	0.1	1.1	1.1
Cash from operating activities
	691	561	50.4	424	338
	—	37.2	−17.1	−70.8	−37.2
	—	598	33.3	353	300
	—	140	12.6	122	63.0
	—	458	20.7	230	237
Cash from investing activities
	—	131	17.3	209	53.6
	—	1.0	0.1	0.9	0.4
	—	0.0	0.0	0.0	26.6
	—	26.2	3.4	30.9	10.4
	—	−145	8.9	36.3	−190
	—	−248	−4.9	−141	−259
Cash from financing activities
	—	0.0	0.0	0.0	275
	—	0.0	0.0	0.0	40.2
	—	0.0	0.0	0.0	5.3
	—	−6.5	0.6	12.5	5.0
	—	38.4	0.0	28.4	17.7
	—	2.8	2.7	5.2	9.1
	—	36.3	3.0	22.7	10.2
	—	0.0	0.2	0.0	0.0
	—	−70.9	−6.5	−68.7	198
	—	139	9.3	20.8	176
	—	−0.6	0.0	0.0	0.0
	—	138	9.3	20.8	176
	—	634	496	403	382
Reference items
	714	601	52.9	459	339
	22.5%	20.4%	20.2%	21.1%	18.3%
	328	328	3.4	21.6	184
	—	352	−26.1	3.9	—
	₹7.23	₹7.23	₹0.07	₹0.48	₹4.06
	43.62×	—	—	—	—
	—	1.09×	0.54×	0.73×	0.89×
	—	140	12.6	122	63.0
	—	2.8	2.7	5.2	9.1

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MARKSANS₹315.35

Marksans Pharma Ltd.

· Pharma & Health

₹ CrorePeersGRANULES METROPOLIS PARKHOSPS JLHL HCG RUBICON SHILPAMED SPARCMcap ₹14,290 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	51.9	74.3	8.3	98.6	—
+ Finance Costs	9.1	11.2	1.2	24.1	—
+ Interest Income	-12.0	-33.8	-3.0	-27.7	—
+ Fair Value (Gains) / Losses	10.8	-4.3	0.4	2.9	—
+ Unrealised FX (Gain) / Loss	-0.2	3.0	-0.5	-22.4	—
+ Other Non-cash Items	14.7	5.2	0.6	25.2	—
+ Other — Cash Effects are Investing / Financing	0.0	-0.1	-0.1	-1.2	—
Changes in Working Capital
+ Inventories	-44.9	-112.7	-19.5	-38.7	—
+ Trade Receivables — Current	-27.5	-37.2	-7.8	-31.4	—
+ Other Financial Assets — Current	4.9	-0.3	-0.0	-0.1	—
+ Other Financial Assets — Non-current	-0.7	0.8	-0.1	-0.2	—
+ Other Current Assets	-23.9	-22.3	-1.6	-0.8	—
+ Other Non-current Assets	-2.7	-7.3	-0.0	0.1	—
+ Trade Payables — Current	22.4	31.4	3.2	9.4	—
+ Other Financial Liabilities — Current	-46.9	3.3	0.4	1.1	—
+ Other Current Liabilities	6.2	16.1	1.3	-1.9	—
+ Provisions — Current	0.5	0.9	-0.1	0.1	—
+ Provisions — Non-current	1.1	1.1	0.1	-0.0	—
Cash from Operating Activities
Profit Before Tax (per I/S)	337.7	423.5	50.4	560.6	690.5
+ Total Adjustments (incl. Working Capital)	-37.2	-70.8	-17.1	37.2	—
Cash from Operations (pre-tax)	300.4	352.8	33.3	597.8	—
+ Income Taxes Paid	63.0	122.3	12.6	139.7	—
Cash from Operating Activities	237.4	230.4	20.7	458.1	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	53.6	208.8	17.3	130.5	—
+ Disp of Fixed Assets	0.4	0.9	0.1	1.0	—
+ Purchase of Investments (Equity / Debt)	26.6	0.0	0.0	0.0	—
+ Interest Received — Investing	10.4	30.9	3.4	26.2	—
+ Other Inflows / (Outflows) — Investing	-189.8	36.3	8.9	-145.0	—
Cash from Investing Activities	-259.2	-140.8	-4.9	-248.3	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	274.7	0.0	0.0	0.0	—
+ Buyback / Redemption of Own Shares	40.2	0.0	0.0	0.0	—
+ Proceeds from Borrowings	5.3	0.0	0.0	0.0	—
+ Repayment of Borrowings	5.0	12.5	0.6	-6.5	—
+ Payment of Lease Liabilities	17.7	28.4	0.0	38.4	—
+ Interest Paid	9.1	5.2	2.7	2.8	—
+ Dividends Paid	10.2	22.7	3.0	36.3	—
+ Income Taxes (Paid) / Refund — Financing	0.0	0.0	0.2	0.0	—
Cash from Financing Activities	197.8	-68.7	-6.5	-70.9	—
Net Changes in Cash (pre-FX)	176.0	20.8	9.3	138.9	—
+ Effect of FX Rate Changes on Cash	0.0	0.0	0.0	-0.6	—
Net Changes in Cash	176.0	20.8	9.3	138.4	—
Closing Cash	382.4	403.3	495.8	634.1	—
Reference Items
EBITDA	339.3	458.6	52.9	600.8	713.7
EBITDA Margin %	18.32	21.06	20.16	20.36	22.50
Free Cash Flow (CFO − Capex)	183.8	21.6	3.4	327.6	327.6
Free Cash Flow to Equity	—	3.9	-26.1	352.1	—
Free Cash Flow per Basic Share	4.06	0.48	0.07	7.23	7.23
Price to Free Cash Flow	—	—	—	—	43.62
Cash Flow to Net Income	0.89	0.73	0.54	1.09	—
Cash Paid for Taxes	63.0	122.3	12.6	139.7	—
Cash Paid for Interest	9.1	5.2	2.7	2.8	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.